ERBB2 and breast cancer: Notwithstanding the fact that MCL-1 is not the only protein that is downregulated after treatment with dinaciclib, the lack of its pro-apoptotic partner, NOXA, in HER2-amplified breast cancers4 makes it likely the most important dinaciclib target in HER2-amplified breast cancers.